Trial · NCT02232425
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Fold Change in Geometric Mean Intravaginal Ejaculatory Latency Time (IELT) | Drug: IX-01 | 2.1 | 95% Confidence Interval 1.5 to 3.1 | No units for fold change | |
| Mean Fold Change in Geometric Mean Intravaginal Ejaculatory Latency Time (IELT) | Placebo | 1.1 | 95% Confidence Interval 0.7 to 1.8 | No units for fold change | |
| Proportion of Participants Rating Their PE as Better or Much Better, on the Clinical Global Impression of Change (CGIC) Scale | Drug: IX-01 | Better/Much Better | 0.17 | proportion of participants | |
| Proportion of Participants Rating Their PE as Better or Much Better, on the Clinical Global Impression of Change (CGIC) Scale | Placebo | Better/Much Better | 0 | proportion of participants | |
| Proportion of Participants Rating Their PE as Better or Much Better, on the Clinical Global Impression of Change (CGIC) Scale | Drug: IX-01 | Any Improvement | 0.44 | proportion of participants | |
| Proportion of Participants Rating Their PE as Better or Much Better, on the Clinical Global Impression of Change (CGIC) Scale | Placebo | Any Improvement | 0.13 | proportion of participants | |
| Proportion of Participants With Greater Than or Equal to (≥) 2.5 Fold Increase in Intravaginal Ejaculatory Latency Time (IELT) | Drug: IX-01 | 0.31 | 95% Confidence Interval 0.14 to 0.54 | Proportion of participants | |
| Proportion of Participants With Greater Than or Equal to (≥) 2.5 Fold Increase in Intravaginal Ejaculatory Latency Time (IELT) | Placebo | 0.07 | 95% Confidence Interval 0.01 to 0.32 | Proportion of participants | |
| Mean Fold Change in Arithmetic IELT (Intravaginal Ejaculatory Latency Time) | Drug: IX-01 | 3.6 | 95% Confidence Interval 2.2 to 5.0 | No units for fold change | |
| Mean Fold Change in Arithmetic IELT (Intravaginal Ejaculatory Latency Time) | Placebo | 1.8 | 95% Confidence Interval 0.9 to 2.7 | No units for fold change | |
| Mean Change in Score on Control of Timing of Ejaculation | Drug: IX-01 | 0.42 | 95% Confidence Interval -0.08 to 0.93 | units on a scale | |
| Mean Change in Score on Control of Timing of Ejaculation | Placebo | -0.03 | 95% Confidence Interval -0.59 to 0.53 | units on a scale | |
| Mean Change in Score on Ejaculation-related Personal Distress | Drug: IX-01 | 0.63 | 95% Confidence Interval 0.37 to 0.88 | units on a scale | |
| Mean Change in Score on Ejaculation-related Personal Distress | Placebo | 0.03 | 95% Confidence Interval -0.34 to 0.40 | units on a scale | |
| Proportion of Participants With ≥ 1 Category of Improvement in Satisfaction With Sexual Intercourse, on the Premature Ejaculation Profile (PEP) Questionnaire | Drug: IX-01 | 0.53 | 95% Confidence Interval 0.33 to 0.72 | adjusted proportion of participants | |
| Proportion of Participants With ≥ 1 Category of Improvement in Satisfaction With Sexual Intercourse, on the Premature Ejaculation Profile (PEP) Questionnaire | Placebo | 0.30 | 95% Confidence Interval 0.13 to 0.56 | adjusted proportion of participants | |
| Proportion of Participants With ≥ 1 Category of Improvement in Control Over Ejaculation During Sexual Intercourse on the Premature Ejaculation Profile (PEP) Questionnaire | Drug: IX-01 | 0.56 | 95% Confidence Interval 0.42 to 0.69 | adjusted proportion of participants | |
| Proportion of Participants With ≥ 1 Category of Improvement in Control Over Ejaculation During Sexual Intercourse on the Premature Ejaculation Profile (PEP) Questionnaire | Placebo | 0.36 | 95% Confidence Interval 0.19 to 0.58 | adjusted proportion of participants | |
| Proportion of Participants With ≥ 1 Category of Improvement in Ejaculation-related Distress on the Premature Ejaculation Profile ( PEP) Questionnaire | Drug: IX-01 | 0.60 | 95% Confidence Interval 0.46 to 0.73 | adjusted proportion of participants | |
| Proportion of Participants With ≥ 1 Category of Improvement in Ejaculation-related Distress on the Premature Ejaculation Profile ( PEP) Questionnaire | Placebo | 0.36 | 95% Confidence Interval 0.19 to 0.57 | adjusted proportion of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02232425/results